Despite the promising safety profiles and potential efficacy observed with recombinant thrombopoietin agonists (rhTpo) such as romiplostim, as well as second-generation TpoRas like eltrombopag in treating post-HSCT thrombocytopenia, the existing studies have several notable limitations. This evidence concerns the gene THPO and Thrombocytopenia.